Innovative Treatments for
Cytokine Release Syndrome
CTO1681: Orally bioavailable, steroid-sparing immunomodulator
for multiple CRS-inducing cytokines
CytoAgents Overview
CytoAgents is developing CTO1681, a novel therapy for the treatment of Cytokine Release Syndrome (CRS), a dangerous and potentially life-threatening overreaction of the immune system, commonly known as Cytokine Storm.
CTO1681 safely downregulates the production of 25+ CRS-inducing cytokines, effectively stopping CRS and rebalancing the body’s immune response. The treatment is applicable across multiple therapeutic areas and is currently in a Phase 1b/2a clinical trial to treat CRS in patients receiving CAR T-cell therapy.
Our Team- HIGHLY SPECIFIC MECHANISM
OF ACTION - DEMONSTRATED EFFICACY IN
MULTIPLE MODELS - PHASE 1 TRIAL COMPLETE
- PHASE 1b/2a INITIATED Q2 2023
- PROVEN SAFETY PROFILE
Clinical Development:
CAR T-Cell Therapy and Bispecific Antibody-Related CRS
Many CAR T patients require hospitalization as a result. Patients often require ICU resources and powerful steroid treatments to treat the Cytokine Storm.
CytoAgents is conducting its Phase 1b/2a clinical trial to treat CRS in patients receiving CAR T-Cell Therapy in oncology. Immunotherapies such as CAR T and Bispecific Antibodies trigger powerful immune responses to fight disease, which often induces CRS. CTO1681’s ability to safely modulate the cytokine response while keeping the immune system functionally intact makes it an ideal CRS treatment in these settings. Effective CRS treatment will not only improve patient outcomes, but also expand patient access to these important, new treatment modalities.
Our Science
MODULATING CYTOKINE AMPLIFICATION
CRS occurs when unchecked cytokine production leads to a cycle of acute inflammation resulting in organ damage and death. CTO1681, a potent EP4 receptor agonist, treats the underlying cause of CRS by targeting the NF-kB, the signaling pathway that plays a critical role in activating and regulating inflammatory immune cells. By interrupting this pathway, CTP1681 effectively forestalls cytokine amplification downregulating cytokine production while leaving the immune system functionally intact.
Learn MorePartners & Investors
CytoAgents has made tremendous progress in the fight against CRS. We have successfully completed Phase 1 Human Clinical Trials and are currently conducting our Phase 1b/2a Clinical Trial to treat CRS in patients receiving CAR T-cell therapy.
Join us as we transform CRS through a novel approach that allows for prevention as well as treatment.
Contact Us